depression and suicidal thoughts. (3) The most common antidepressants used today are SSRIs (selective serotonin reuptake inhibitors).
Unlike SSRIs, Ketamine appears to act on another neurotransmitter (glutamate), opening up the potential for new treatments for depression.
By binding and blocking certain receptors in the brain, Ketamine may strengthen new neural pathways that can positively affect mood, reinforce various cognitive processes, and reduce depressive symptoms. (5)The intriguing possibility for a new approach in treating depression sparked the development of a new Ketamine derivative, esketamine, which works as a nasal spray. (4) So far, esketamine has been approved in the US (2019), Canada (2020), and the UK (2020) as a.Read more on headsupguys.org